Genmab A/S : Voting Results of the Annual General Meeting 2021
April 27, 2021 at 05:11 am
Share
Voting results of the Annual General Meeting 2021
Number of
Share
Number of
Number of
Number of
Number of
Agenda
capital
votes
votes
votes
votes*
valid votes
(%)
FOR
AGAINST
ABSTAIN
1. Report by the Board of Directors on the Company's
-
-
-
-
-
-
activities during the past year
2. Presentation and adoption of the audited Annual Report
2020 and resolution to discharge Board of Directors and
23,328,374
35.68
23,307,421
22,678,704
603,997
24,720
Executive Management from liability
3. Resolution on the distribution of profits as recorded in
23,328,374
35.68
23,307,421
23,302,374
3,289
1,758
the adopted Annual Report
4. Presentation of an advisory vote on the 2020
23,328,374
35.68
23,307,421
21,379,961
1,862,408
65,052
Compensation Report
5. Election of members of the Board of Directors:
Re-election of Deirdre P. Connelly
23,328,374
35.68
23,307,421
21,975,105
-
1,332,316
Re-election of Pernille Erenbjerg
23,328,374
35.68
23,307,421
23,287,548
-
19,873
Re-election of Rolf Hoffmann
23,328,374
35.68
23,307,421
20,909,542
-
2,397,879
Re-election of Dr. Paolo Paoletti
23,328,374
35.68
23,307,421
22,608,033
-
699,388
Re-election of Jonathan Peacock
23,328,374
35.68
23,307,421
22,439,276
-
868,145
Re-election of Dr. Anders Gersel Pedersen
23,328,374
35.68
23,307,421
19,616,907
-
3,690,514
6. Election of auditor: Re-election of
PricewaterhouseCoopers Statsautoriseret
23,328,374
35.68
23,307,421
21,757,719
-
1,549,702
Revisionspartnerselskab
7. Proposals from the Board of Directors:
7(a) Proposal to adopt the Board of Directors'
23,328,374
35.68
23,307,421
13,677,102
8,149,790
1,480,529
remuneration for 2021
7(b) Proposal to amend the Remuneration Policy for the
Board of Directors and Executive Management of Genmab
23,328,374
35.68
23,307,421
23,207,973
89,641
9,807
A/S (decrease of the multiplier of the base fee for the chair
and deputy chair of the Board of Directors)
7(c) Proposal to amend the Remuneration Policy for the
Board of Directors and Executive Management of Genmab
23,328,374
35.68
23,307,421
20,603,097
2,329,650
374,674
A/S (certain other changes)
7(d) Proposal to authorize the Board of Directors to
23,328,374
35.68
23,307,421
22,450,955
728,301
128,165
mandate the Company to acquire treasury shares
7(e) Proposal to authorize the Board of Directors to
increase the share capital of the Company by cash
23,328,374
35.68
23,307,421
21,911,470
1,366,913
29,038
payment and to let the Company issue convertible debt
instruments
7(f) Proposal to authorize the Board of Directors to let the
23,328,374
35.68
23,307,421
23,192,524
108,340
6,557
Company issue warrants
7(g) Proposal to authorize the Board of Directors to
assemble general meetings as wholly virtual general
23,328,374
35.68
23,307,421
22,586,655
503,596
217,170
meetings
8. Authorization of the Chair of the General Meeting to
23,328,374
35.68
23,307,421
23,299,659
2,921
4,841
register resolutions passed by the General Meeting
9. Any other business
-
-
-
-
-
-
* Based on the number of participants at the beginning of the meeting as well as proxy and postal votes received prior to the meeting
Attachments
Original document
Permalink
Disclaimer
Genmab A/S published this content on 27 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 April 2021 09:10:02 UTC.
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.